Stock Surge of Relay Therapeutics: Up By Almost 15% During the Current Week

Biotech company with a focus on cancer shows promising prospects, asserts industry analyst.

, and Administrator

2025 September 14 . 1:25 PM

2 min read

Stock surge of Relay Therapeutics: an ascent of almost 15% this week

Stock Surge of Relay Therapeutics: Up By Almost 15% During the Current Week

In a significant move, Guggenheim Securities has bestowed its prestigious "Best Idea" designation on Relay Therapeutics, sending the company's stock soaring by 3.00% today. The analyst behind this endorsement is Brad Canino, who has also initiated coverage of Relay Therapeutics.

Canino's optimism stems from the promising results of RLY-2608, a treatment currently in late-stage clinical trials. According to Canino, the treatment has shown positive results in clinical studies, and its potential for treating vascular malformations - an orphan disease that frequently affects children - is noteworthy.

The analyst also highlighted the clean safety profile of RLY-2608, which adds to its appeal. The treatment's potential in the treatment of vascular malformations, coupled with its promising clinical results and safety profile, has led Canino to flag Relay Therapeutics as a buy with a price target of $15 per share.

The stock's day's range is between $3.85 and $4.20, reflecting the increased investor interest. The volume of shares traded for Relay Therapeutics today stands at 2,028,132, a significant increase from the average volume of 1,949,913 shares.

Relay Therapeutics reported a gross margin of 41.23% in its second quarter, and the company earned $677,000, a stark contrast to the $0 it earned in the year-ago period. These financial improvements have contributed to the growing confidence in the company.

Multiple analysts have recommended buying Relay Therapeutics, setting an average target price of $62.20. This indicates significant potential upside, and the 52-week range for the stock - $1.77 to $10.72 - suggests that the current stock price of $4.12 presents a promising opportunity for investors.

With a market capitalization of $710M, Relay Therapeutics is poised for growth, and Canino's endorsement and the positive results of RLY-2608 in clinical studies could be the catalyst for further growth in the coming months.